Pharvaris (NASDAQ:PHVS) Sets New 1-Year High - Time to Buy?

Key Points

• Pharvaris shares surged 14.3% to a new 52-week high of $42.02, last trading at $41.30, above its 50-day and 200-day moving averages.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $51.08, despite one downgrade to “Sell.”
• The company missed quarterly earnings expectations, reporting an EPS loss of $0.81 versus the expected $0.75 loss, while insiders sold approximately $4.19 million of stock over the past 90 days.

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $42.02 and last traded at $41.30, with a volume of 493228 shares traded. The stock had previously closed at $35.25.

Wall Street Analyst Weigh In

Several research firms recently commented on PHVS. Wall Street Zen downgraded shares of Pharvaris from a "hold" rating to a "sell" rating in a report on Saturday, July 18th. Guggenheim lifted their price target on Pharvaris from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. Morgan Stanley lifted their target price on Pharvaris from $41.00 to $46.00 and gave the company an "overweight" rating in a report on Thursday, June 25th. HSBC raised shares of Pharvaris to an "overweight" rating in a report on Thursday, August 13th. Finally, Royal Bank Of Canada raised their price objective on shares of Pharvaris from $51.00 to $52.00 and gave the company an "outperform" rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $51.08.

Pharvaris Stock Up 14.3%

The business's 50-day simple moving average is $34.79 and its 200-day simple moving average is $31.12. The stock has a market cap of $2.64 billion, a PE ratio of -13.21 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, equities research analysts anticipate that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Berndt Modig sold 2,292 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer directly owned 130,625 shares in the company, valued at approximately $4,541,831.25. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the transaction, the director owned 315,167 shares of the company's stock, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 118,655 shares of company stock worth $4,188,002 in the last 90 days.

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently bought and sold shares of the business. Quantbot Technologies LP bought a new position in shares of Pharvaris in the 2nd quarter worth $41,000. CoreCap Advisors LLC bought a new stake in Pharvaris during the second quarter valued at about $93,000. Barclays PLC purchased a new position in Pharvaris in the fourth quarter valued at about $77,000. JPMorgan Chase & Co. raised its holdings in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company's stock worth $59,000 after purchasing an additional 783 shares in the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Pharvaris in the fourth quarter worth about $139,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.